HIGHBRIDGE CAPITAL MANAGEMENT
HCM is a global alternative investment management firm launched in 1992. Since its inception, the company has developed a diversified investment platform that includes hedge funds, traditional investment management products and debt and private equity investments with longer-term holding periods. With over 300 employees, including almost 100 investment professionals, HCM manages approximately $21 billion of capital for some of the world's most prominent institutional investors, public and corporate pension funds, endowments, foundations and family offices.
HIGHBRIDGE CAPITAL MANAGEMENT
Industry:
Finance Financial Services Venture Capital
Founded:
1992-01-01
Status:
Active
Contact:
212 287 4000
Email Addresses:
[email protected]
Technology used in webpage:
SPF SSL By Default Google Font API Domain Not Resolving Google Maps Microsoft Azure DNS Cloudflare JS CDN JS Cloudflare DNS Akamai Hosted
Current Employees Featured
Scott Kapnick
Scott Kapnick Managing Partne & Board Member @ Highbridge Capital Management Managing Partne & Board Member
Scott Kapnick
Scott Kapnick Chief Executive Officer of Highbridge Principal Strategies @ Highbridge Capital Management Chief Executive Officer of Highbridge Principal Strategies
Jonathan Segal
Jonathan Segal Portfolio Manager, Managing Director @ Highbridge Capital Management Portfolio Manager, Managing Director
Founder
Glenn Dubin
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2021-12-28 | CompoSecure | Highbridge Capital Management investment in Post-IPO Equity - CompoSecure | 175 M USD |
2021-12-22 | Urgently | Highbridge Capital Management investment in Debt Financing - Urgently | 75 M USD |
2021-12-08 | BigBear.ai | Highbridge Capital Management investment in Post-IPO Debt - BigBear.ai | 200 M USD |
2021-11-04 | Lime | Highbridge Capital Management investment in Convertible Note - Lime | 418 M USD |
2021-09-20 | Santhera Pharmaceuticals | Highbridge Capital Management investment in Post-IPO Debt - Santhera Pharmaceuticals | 25 M CHF |
2021-09-20 | Santhera Pharmaceuticals | Highbridge Capital Management investment in Post-IPO Equity - Santhera Pharmaceuticals | 20 M CHF |
2021-05-24 | Quotient Biodiagnostics | Highbridge Capital Management investment in Post-IPO Debt - Quotient Biodiagnostics | 95 M USD |
2021-02-16 | Gamida Cell | Highbridge Capital Management investment in Post-IPO Debt - Gamida Cell | 75 M USD |
2020-06-04 | Santhera Pharmaceuticals | Highbridge Capital Management investment in Post-IPO Debt - Santhera Pharmaceuticals | 20 M CHF |
2020-03-12 | Protalix BioTherapeutics | Highbridge Capital Management investment in Post-IPO Equity - Protalix BioTherapeutics | 43.7 M USD |